Timo M.
- Country
- Finland
- Department
- Department of Urology
Research Overview
- Evaluation of Atorvastatin on Progression of Metastatic or High-Risk Recurrent Prostate Cancer During Androgen Deprivation Therapy: A Phase 3 Randomized Controlled Trial
- Efficacy and Safety Evaluation of Enzalutamide and Leuprorelin Acetate in High-Risk Nonmetastatic Prostate Cancer Post-Definitive Therapy
Data & Insights
Has run more than one trial at 5 of 66 partner sites.
Specializations
Prostate Cancer Progression Control
Timo Marttila’s clinical research activity is centered on prostate cancer with a focus on disease control after androgen deprivation therapy, particularly in settings where progression toward castration resistance is a concern.
- Advanced prostate cancer
- Castration-resistant disease
- Hormone-sensitive treatment pathways
The therapeutic interest in this area includes strategies aimed at delaying progression in men with metastatic or high-risk recurrent disease.
Androgen Deprivation and Hormonal Therapy
His trial portfolio includes work on hormonal treatment approaches for prostate cancer, with attention to combinations and comparisons involving leuprolide and enzalutamide in patients with high-risk disease.
- Androgen deprivation therapy
- Enzalutamide
- Leuprolide
This area reflects a clear therapeutic interest in optimizing endocrine-based management for patients whose disease continues to progress after definitive treatment.
Metastatic Castration-Resistant Prostate Cancer
Another major focus is metastatic castrate resistant prostate cancer (mCRPC), including treatment options for disease that has spread to bone and worsened after prior antihormonal therapy.
- Bone metastatic prostate cancer
- Second-line antihormonal therapy
- Resistant metastatic disease
His work in this domain is closely linked to therapeutic decision-making for advanced, treatment-refractory prostate cancer.
Radiopharmaceutical and Bone-Targeted Treatment
Marttila is also involved in research on radium-223 dichloride, a radiopharmaceutical used in prostate cancer with skeletal involvement, highlighting interest in therapies directed at metastatic bone disease.
- Radium-223 dichloride
- Bone metastases
- Targeted cancer treatment
This area connects oncologic care with treatments designed to address the burden of metastatic spread to the skeleton.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.